Specialty Pharmacy

In a single-center study, investigators reviewed charts of 25 children with inflammatory bowel disease transitioning from infliximab to the biosimilar infliximab-dyyb for maintenance.

Specialty pharmacists—those caring for patients with serious, sometimes life-threatening conditions such as cancer or rheumatologic disease—are not immune from the ongoing labor crisis.

The imaging agent and visualization system will be an adjunct to standard of care to reduce residual cancer in the lumpectomy cavity during initial surgery.

Beremagene geperpavec completely closed severe blistering and wounds in more than half of all patients with dystrophic epidermolysis bullosa with specific mutations.

Pegfilgrastim-pbbk is a leukocyte growth factor developed to reduce the onset of infection in patients with non-myeloid malignancies administered myelosuppressive anticancer medications associated with a clinically significant rate of febrile neutropenia.

Fran Gregory, PharmD, MBA, vice president of Emerging Therapies at Cardinal Health, discussed the role biosimilars are playing in the pharmaceutical market as well as in patient access.

Lili Wang, MD, PhD, discusses her research investigating how METTL3 regulates RNA splicing dysregulation and contributes to CLL growth.

With a growing expectation for individualized and personalized care, medically integrated pharmacies have a great opportunity to support patients and the care team.

Study of cell exhaustion in immunotherapy-resistant tumors could significantly improve the benefits of cancer immunotherapy for patients with treatment resistant types of cancer.

Commonly, essential yet routine and time-consuming tasks, such as answering phone calls, scheduling appointments, or other administrative work, prevent health care workers from focusing on more value-added and enjoyable job functions.

The extra surveillance by a specialty pharmacy teams allows for faster initiation of therapy, earlier recognition of adverse effects, and promotes patient safety.

Importantly, Sullivan said data show that adverse events in the home infusion environment are no higher than in any other setting.

Approximately 43 total specialty drugs come to the market each year, on average.

Shweta S. Namjoshi, MD, MPH, CNSC, discusses the role of the pharmacists in gastrointestinal care and the differences in care for pediatrics and adults.

Kimlin Tam Ashing, PhD, discusses her research assessing effective interventions in ethnic minority communities to increase colorectal cancer screenings.

Pharmacists, in particular, must be cautious and deliberate in using ChatGPT to ensure that its benefits are fully realized while minimizing risk and misinformation.

There are common symptoms experienced in the workplace that may be linked to hormones instead of stress.

Alpelisib plus the antioxidant N-acetylcysteine sensitizes NF1 knockout cells to PI3Kα inhibition and reverts their glycolytic phenotype in patients with advanced forms of breast cancer.

The study will be conducted in Brazil, where PrEP use for HIV continues to be lower than desired.

The novel antibody-drug conjugate is the first to demonstrate overall survival benefits in patients who were already treated with therapy.

There are still significant unresolved issues in artificial intelligence and machine learning, which must be addressed before they can be safely and effectively used more broadly in medicine.

At least 58% of mice treated with combined CRISPR therapies showed signs of complete HIV-1 viral elimination.

The therapy had a clinically meaningful response in patients with relapsed or refractory (R/R) follicular lymphoma and R/R mantle cell lymphoma.

PSG speakers present findings of the report at AXS23 and explain some of the notable results.

Gregory also discussed the differences between specialty pharmacy distribution and physician’s office distribution, and the benefits of each for patients.

Study examines association between breast cancer survival and neighborhood-level measures such as socioeconomic status.

In addition to 2 FDA-approved options, several clinical trials are investigating other potential treatments for immunoglobulin A nephropathy.

In addition to offering convenience and ease of access, Sullivan said allowing patients to receive care at home empowers them and improves quality of life.

Biosimilars are also expanding rapidly, offering new opportunities for payers, patients, and providers.

Panelists at AXS23 conference agree that the patient’s voice is the most critical, whether it is related to drug manufacturing, delivery, or marketing.